Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557315 | 0.82 | — | — | |
| SCHEMBL3009125 | 0.81 | HTR2C (0.36) | HTR2CHTR2AHTR2BPNMTADORA1 | |
| SCHEMBL2994809 | 0.79 | HTR2C (0.35) | HTR2CHTR2AHTR2BADORA1 | |
| SCHEMBL2994722 | 0.76 | HTR2C (0.33) | HTR2CHTR2AHTR2BADORA1 | |
| SCHEMBL2995420 | 0.76 | HTR2C (0.33) | HTR2CHTR2AHTR2B | |
| SCHEMBL3000284 | 0.75 | PNMT (0.40) | HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL3007669 | 0.73 | HTR2C (0.31) | HTR2CADORA1 | |
| Hydrochloric Acid SCHEMBL2991349 | 0.73 | PNMT (0.39) | HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL13266269 | 0.69 | PNMT (0.39) | HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL13560094 | 0.65 | PNMT (0.38) | PNMTADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778243-B1 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1778243-B1 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20100190772-A1 | Substituted Azepine Derivatives As Serotonin Receptor Modulators | BENNANI YOUSSEF L | 2010-07-29 | — | — | US | disclosed |
| US-20100190772-A1 | Substituted Azepine Derivatives As Serotonin Receptor Modulators | BENNANI YOUSSEF L | 2010-07-29 | — | — | US | disclosed |
| US-20100190772-A1 | Substituted Azepine Derivatives As Serotonin Receptor Modulators | BENNANI YOUSSEF L | 2010-07-29 | — | — | US | disclosed |
| US-7718647-B2 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718647-B2 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718647-B2 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | HTR5A, HTR4, HTR7 | HTR2C 5/4885HTR2A 6/4885HTR2B 14/4885 |
| US-20100190772-A1 | Substituted Azepine Derivatives As Serotonin Receptor Modulators | HTR5A, HTR4, HTR2C | HTR2C 3/4885HTR2A 5/4885HTR2B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.